SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?

Sponsor
Northwestern University (Other)
Overall Status
Completed
CT.gov ID
NCT02568930
Collaborator
National Institute on Aging (NIA) (NIH)
694
13
65.5
53.4
0.8

Study Details

Study Description

Brief Summary

The purpose of this study is to compare health-related quality of life (HRQOL) outcomes in older (60-80 years) advanced heart failure (HF) patients who undergo heart transplantation (HT) or mechanical circulatory support (MCS) as a permanent implant (i.e., destination therapy [DT]) and their caregivers. Our study will contribute to better patient-centered care of older advanced HF patients and their caregivers, by informing decision making and guiding strategies to enhance post-operative HRQOL.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The purpose of this study is to compare health-related quality of life (HRQOL) outcomes in older (60-80 years) advanced heart failure (HF) patients who undergo heart transplantation (HT) or mechanical circulatory support (MCS) as a permanent implant (i.e., destination therapy [DT]) and their caregivers, risk factors for poor HRQOL, adverse event and symptom burden, and quality-adjusted life years (QALYs). Advanced HF patients, 60-80 years of age, are an appropriate target group for this study because they are receiving HTs and MCS devices more frequently, and despite a greater risk for poor clinical outcomes, they have acceptable rates of survival. Using a prospective, longitudinal design, our multi-site comparative effectiveness research will compare HRQOL outcomes in patients who receive HT or DT MCS and their caregivers, from baseline to 2 years post-operatively. The primary aim of this proposed study is to determine whether older advanced HF patients who undergo DT MCS, as compared to patients who undergo HT, experience non-inferior change in overall HRQOL (primary), and domains of HRQOL (physical, mental, and social) from baseline through 2 years after surgery. Secondary Aims are (1.) to determine whether caregivers of older advanced HF patients who undergo DT MCS, compared to caregivers of older advanced HF patients who undergo HT, experience non-inferior change in overall HRQOL and domains from baseline through 2 years after surgery; (2.-3.) to identify risk factors related to poorer overall HRQOL in older DT MCS patients and their caregivers, as compared to older HT patients and their caregivers, at 2 years after surgery; (4.) to determine whether older advanced HF patients who undergo DT MCS, as compared to patients who undergo HT, have non-inferior rates of freedom from adverse events & symptoms at 1 and 2 years after surgery; and (5) to evaluate the distribution of QALYs in older advanced HF patients who undergo DT MCS, as compared to patients who undergo HT at 2 years after surgery. Our proposed study will contribute to better patient-centered care of older advanced HF patients and their caregivers, by informing decision making and guiding strategies to enhance post-operative HRQOL.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    694 participants
    Observational Model:
    Other
    Time Perspective:
    Prospective
    Official Title:
    SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?
    Actual Study Start Date :
    Oct 15, 2015
    Actual Primary Completion Date :
    Mar 31, 2021
    Actual Study Completion Date :
    Mar 31, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Heart Transplantation (HT)

    The cohort includes advanced heart failure patients (60-80 years of age) listed for HT and their caregivers.

    Mechanical Circulatory Support (MCS)

    The cohort includes advanced heart failure patients (60-80 years of age) scheduled for DT MCS and their caregivers.

    Outcome Measures

    Primary Outcome Measures

    1. Non-inferior change in patient HRQOL [baseline through 2 years after surgery]

      To determine whether older advanced HF patients who undergo DT MCS, as compared to patients who undergo HT, experience non-inferior change in overall HRQOL (primary outcome) and HRQOL domains (physical, mental, and social [secondary outcomes]) from baseline through 2 years after surgery.

    Secondary Outcome Measures

    1. Non-inferior change in caregiver HRQOL [baseline through 2 years after surgery]

      To determine whether caregivers of older advanced HF patients who undergo DT MCS, as compared to caregivers of older advanced HF patients who undergo HT, experience non-inferior change in overall HRQOL and HRQOL domains from baseline through 2 years after surgery.

    2. Risk factors related to poorer patient overall HRQOL [2 years after surgery]

      To identify risk factors related to poorer overall HRQOL in older DT MCS patients, as compared to older HT patients, at 2 years after surgery.

    3. Risk factors related to poorer caregiver overall HRQOL [2 years after surgery]

      To identify risk factors related to poorer overall HRQOL in caregivers of older DT MCS patients, as compared to caregivers of older HT patients, at 2 years after surgery.

    4. Non-inferior rates of freedom from adverse events & symptoms [1 and 2 years after surgery]

      To determine whether older advanced HF patients who undergo DT MCS, as compared to patients who undergo HT, have non-inferior rates of freedom from adverse events & symptoms at 1 & 2 years after surgery.

    5. Distribution of QALYs [2 years after surgery]

      To evaluate the distribution of QALYs in older advanced HF patients who undergo DT MCS, as compared to patients who undergo HT at 2 years after surgery.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Patient Inclusion Criteria:
    1. Advanced HF and listed with the United Network for Organ Sharing (UNOS) for a "primary" HT or scheduled to receive a "primary" DT LVAD;

    2. Ages 60-80 years and able to speak, read, and understand English;

    3. Willing to participate and ability to provide informed consent.

    Caregiver Inclusion criteria:
    1. Primary caregiver, identified by the patient, prior to DT MCS or while a candidate for HT;

    2. Unpaid family member or friend who helps the patient with self-care;

    3. Age > 21 years and able to speak, read, and write English;

    4. Willing to participate and ability to provide informed consent.

    Patient Exclusion criteria

    1. Patient has a prior HT or MCS device

    2. Patient is listed for multiple organ transplantation (i.e., heart/lung, heart/kidney, etc.)

    Caregiver Exclusion criterion:
    1. Patient refusal to participate.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Alabama at Birmingham (UAB) Birmingham Alabama United States 35294
    2 Florida Hospital Orlando Florida United States 32803-1248
    3 Northwestern University Chicago Illinois United States 60611
    4 Advocate Christ Medical Center Oak Lawn Illinois United States 60453
    5 University of Michigan Ann Arbor Michigan United States 48109
    6 University of Minnesota Medical Center-Fairview Health Services Minneapolis Minnesota United States 55454
    7 Saint Luke's Hospital Kansas City Missouri United States 64111
    8 Washington University Saint Louis Missouri United States 63110
    9 Columbia University New York New York United States 10032-3702
    10 Cleveland Clinic Cleveland Ohio United States 44195
    11 The Ohio State University (OSU) Columbus Ohio United States 43210
    12 University of Pittsburgh Medical Center (UPMC) Pittsburgh Pennsylvania United States 15213
    13 University of Wisconsin-Madison Madison Wisconsin United States 53706-1490

    Sponsors and Collaborators

    • Northwestern University
    • National Institute on Aging (NIA)

    Investigators

    • Principal Investigator: Kathleen Grady, RN, PhD, Northwestern University

    Study Documents (Full-Text)

    More Information

    Publications

    None provided.
    Responsible Party:
    Kathleen Grady, Professor, Feinberg School of Medicine, Northwestern University
    ClinicalTrials.gov Identifier:
    NCT02568930
    Other Study ID Numbers:
    • STU00200851
    • 1R01AG047416
    First Posted:
    Oct 6, 2015
    Last Update Posted:
    Feb 16, 2022
    Last Verified:
    Nov 1, 2021
    Keywords provided by Kathleen Grady, Professor, Feinberg School of Medicine, Northwestern University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 16, 2022